Monalizumab is administered either as a monotherapy or in combination with other therapeutic antibodies, such as durvalumab, which targets PD-L1, or cetuximab, which targets the epidermal growth factor receptor (EGFR) expressed by tumor cells [10,11]. This evidence concerns the gene CD274 and neoplasm.